Companies in #Cardiometabolic

Alnylam Pharmaceuticals (NASDAQ: ALNY) is the leading RNAi therapeutics company, with six approved products (Onpattro, Givlaari, Oxlumo, Amvuttra, Qfitlia, and the Leqvio collaboration with Novartis) and a deep pipeline in cardiometabolic, hepatic infectious disease, and CNS indications. Alnylam's approved medicines target transthyretin amyloidosis (Onpattro, Amvuttra), acute hepatic porphyria (Givlaari), primary hyperoxaluria type 1 (Oxlumo), and hemophilia A and B (Qfitlia). Leqvio (inclisiran), licensed to and commercialized by Novartis, targets LDL cholesterol.

AI-enabled structure-based drug discovery company mapping allosteric binding sites on proteins and RNA to develop precision small molecule therapeutics.

Cardiometabolic drug developer known as Ji Xing Pharmaceuticals in China, in-licensing and developing cardiovascular and metabolic assets including the oral GLP-1 candidate CX11 for obesity.

Services: Global biopharmaceutical group; CSL Behring develops plasma-derived and recombinant therapeutic products for bleeding disorders, immune deficiencies, CIDP, hereditary angioedema, and Alpha-1 Antitrypsin Deficiency; Seqirus produces influenza vaccines; CSL Vifor addresses iron deficiency and nephrology

Genentech, a member of the Roche Group, is a leading biotechnology company pioneering breakthrough medicines for serious diseases. With a 40+ year history of biotech innovation, Genentech develops therapeutics across oncology, immunology, neuroscience, ophthalmology, and infectious diseases, and is currently undergoing a strategic R&D restructuring in 2026.

Ionis Pharmaceuticals (NASDAQ: IONS) is a Carlsbad, California-based antisense oligonucleotide (ASO) drug discovery and development company with a deep pipeline spanning neurology, cardiometabolic disease, renal disease, and rare disorders.

Danish biotech whose nGen platform discovers fully synthetic oral macrocyclic peptides (nCycles) that pair biologic-like target specificity with the convenience of an oral pill.

Services: Global healthcare company formed in November 2020 via Mylan-Upjohn combination; portfolio spans branded (Xulane, Yupelri, Effient, Dilantin, Cordarone, Sarafem, Dymista), generics (~1,400 molecules across all therapeutic areas), biosimilars, complex generics; therapeutic focus: cardiology, infectious disease, immunology, oncology, ophthalmology, dermatology, respiratory, CNS; significant emerging markets presence through legacy Mylan platforms; now executing Phase II of strategic plan with portfolio optimization